Enzyme News and Research

RSS

Neutralization of SARS-CoV-2 by plant-made neutralizing monoclonal antibodies

In a recent study published in the journal Vaccines, researchers developed plant-based monoclonal antibodies (mAbs) against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2).

17 May 2022

A study of SARS-CoV-2-mRNA booster vaccinations in immunocompromised patients

In a recent study published in the journal Frontiers in Immunology, researchers assessed the immune responses induced by vaccination with the messenger ribonucleic acid (mRNA)-1273 vaccine or the BNT162b2 vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections among immunocompromised individuals.

17 May 2022

Broad-spectrum polymeric antivirals against SARS-CoV-2

In a recent study published in the journal Advanced Science, researchers evaluated the potential and applicability of macromolecular viral inhibitors against respiratory viral pathogens.

17 May 2022

Factors impacting anti-SARS-CoV-2 antibodies in healthcare personnel

In a recent study posted to the medRxiv* preprint server, researchers assessed variables that influence anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody titers in medical professionals.

16 May 2022

Why do diabetic patients have more severe SARS-CoV-2 infections?

A recent study published in the journal Cell Metabolism illustrated the function of angiotensin-converting enzyme 2 (ACE2) in renal severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection among diabetic patients.

16 May 2022

SARS-CoV-2 Omicron BA.2 differs antigenically from previous variants

Researchers observed that the SARS-CoV-2 Omicron BA.2 variant is immunologically different from other variants, including Omicron BA.1.

16 May 2022

Super-antibody UT28K shows broad-spectrum activity against SARS-CoV-2 variants

A study, published online in the journal mAbs, describes a novel mAb, UT28K, that has promising broadly neutralizing activity against the SARS-CoV-2 virus.

15 May 2022

Artificial proteins as specific and versatile neutralizing binders targeting the spike of SARS-CoV-2

Researchers demonstrated that the biosynthetic proteins called αReps addressing the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike (S) protein could be novel SARS-CoV-2 antivirals

13 May 2022

The potential role of the gut microbiome in modifying patient responses to statin therapy

Researchers discovered strong links between human gut microbiome makeup and statin on- and off-target effects, probably beneficial in medication tailoring.

13 May 2022

Direct infection and replication of influenza virus in cardiomyocytes is a primary determinant of cardiac pathology associated with severe influenza

Researchers generated a recombinant influenza virus expressing micro ribonucleic acid (miRNAs) expressed in cardiomyocytes to infect mice, which served as a model to study the etiology of influenza-associated cardiac pathology.

13 May 2022

Researchers identify compounds from Aspergillus that may be effective against SARS-CoV-2

Researchers from Ain Shams University have been exploring the use of compounds isolated from Aspergillus sp. against SARS-CoV-2.

13 May 2022

Development of a novel surface plasmon resonance-based assay to determine kinetics of SARS-CoV-2 spike – human ACE2 interaction

A team of scientists has recently studied the kinetic and thermodynamic characteristics of interaction between human ACE2 and spike receptor-binding domains of different variants of SARS-CoV-2.

13 May 2022

SARS-CoV-2 N-terminal domain modulates S1/S2 cleavage and spike-mediated functions

In a recent study posted to the bioRxiv* preprint server, researchers explored the role of the N-terminal domain (NTD) of the severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) spike (S) protein in SARS-CoV-2 fusion with the host membranes and coronavirus disease 2019 (COVID-19).

12 May 2022